Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- IND for Cancer Photoimmunotherapy RM-1995 Accepted in US: Rakuten Medical
December 17, 2021
- Chugai In-Licenses Sarepta’s DMD Gene Therapy from Roche
December 17, 2021
- Biogen/Eisai to Begin Aduhelm Confirmatory Study Next Year
December 17, 2021
- Chugai Terminates Development of Atea’s COVID-19 Drug in Japan
December 17, 2021
- Moderna to Develop All Global Pipeline Assets in Japan without Delay: Local Chief
December 17, 2021
- Shionogi Pharma Eyes 10 Billion Yen Sales in CDMO Business in FY2022
December 17, 2021
- Novavax’s COVID-19 Vaccine Filed in Japan: Takeda
December 16, 2021
- ADC Programs on a Roll, Daiichi Sankyo Got Off to Good Start towards Mid-Term Goal: CEO
December 16, 2021
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- Nobuhide Shinizu to Lead Insmed Japan from January
December 16, 2021
- Takeda Sets Up New Manufacturing Line for Alofisel at Osaka Plant
December 16, 2021
- Kyowa Kirin Files Lumicef for Systemic Sclerosis in Japan
December 16, 2021
- Sumitomo Dainippon Calls Off PIII Cancer Vaccine Study due to Low Probability of Success
December 16, 2021
- Generic Makers Scrambling to Respond to MHLW Request to Lift Shipment Restrictions, Wholesalers Fret Further Confusion
December 15, 2021
- Amenalief Filed for Recurrent Herpes Simplex in Japan: Maruho
December 15, 2021
- Enhertu Filed for Second-Line Breast Cancer Use in Japan: Daiichi Sankyo
December 15, 2021
- Sales Reps’ Online Detailing Jumped 58.7% YOY in October: Intage
December 15, 2021
- Chugai to Tackle Challenging Disease Arenas with Mid-Sized Molecules: R&D Confab
December 14, 2021
- Research Foundation Set Up at Kyoto University after Opdivo Settlement
December 14, 2021
- Sanofi Eyes 2022 Japan NDA for Rare Blood Disease Drug on Positive Data
December 14, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…